Terms: = Gastric cancer AND CgA AND Prognosis
33 results:
1. Biomarkers in neuroendocrine neoplasms.
Zouli C; Zisimopoulou E; Chrisoulidou A
Hell J Nucl Med; 2023; 26 Suppl():44-48. PubMed ID: 37658563
[TBL] [Abstract] [Full Text] [Related]
2. Clinicopathological features and differential diagnosis of gastric metastases.
Chen W; Liu C; Liu Y; Yuan J; Wang Z
World J Surg Oncol; 2023 Aug; 21(1):258. PubMed ID: 37608278
[TBL] [Abstract] [Full Text] [Related]
3. Clinicopathological characteristics of gastric adenocarcinoma with enteroblastic differentiation and gastric adenocarcinoma with enteroblastic marker expression.
Abe D; Akazawa Y; Yatagai N; Hayashi T; Ueyama H; Mine S; Fukunaga T; Nagahara A; Yao T; Saito T
Virchows Arch; 2023 Sep; 483(3):405-414. PubMed ID: 37581693
[TBL] [Abstract] [Full Text] [Related]
4. Exploring the molecular characteristics of the malignant potential of gastric adenocarcinoma with enteroblastic differentiation.
Wang Y; Wei X; Ke B; Liu J; Guo Y; Liu Y; Chen Y; Ding T; Wang Y; Meng B; Sun B; Zang F
Histopathology; 2023 Oct; 83(4):631-646. PubMed ID: 37356975
[TBL] [Abstract] [Full Text] [Related]
5. [Analysis of clinicopathological characteristics, therapeutic strategy and prognosis of 501 patients with gastric neuroendocrine neoplasms attending a single center].
Zhang BL; Lu YX; Liang WQ; Gao YH; Xi HQ; Wang XX; Zhang KC; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):459-466. PubMed ID: 37217354
[No Abstract] [Full Text] [Related]
6. [Clinicopathological characteristics of gastric SMARCA4-deficient undifferentiated/rhabdoid carcinoma].
Wu JY; Jiang K; Yan LJ; Yin LS; Huang XZ; Jia L; Sun Y
Zhonghua Bing Li Xue Za Zhi; 2023 May; 52(5):447-453. PubMed ID: 37106285
[No Abstract] [Full Text] [Related]
7. Clinicopathological and molecular characteristics of the alpha-fetoprotein-producing gastric cancer: emphasis on two major subtypes.
Lu J; Jin M; Zhou X; Chen X; Shao Y; Jiang X
APMIS; 2022 Mar; 130(3):169-180. PubMed ID: 34862662
[TBL] [Abstract] [Full Text] [Related]
8. [Clinicopathological features and survival analysis of gastric cancer patients with neuroendocrine differentiation after radical resection].
Yu S; Lyu MZ; Luo RK; Liu FL; Liu TS
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):426-432. PubMed ID: 34000772
[No Abstract] [Full Text] [Related]
9. Risk factors for progression of appendiceal neuroendocrine tumours: low-stage tumours <5 mm appear to be overwhelmingly indolent and may merit a separate designation.
Noor M; Huber AR; Cates JMM; Gonzalez RS
Histopathology; 2021 Sep; 79(3):416-426. PubMed ID: 33754384
[TBL] [Abstract] [Full Text] [Related]
10. Epstein-Barr Virus Positive gastric cancer: A Distinct Subtype Candidate for Immunotherapy.
Pereira MA; Batista DAM; Ramos MFKP; Cardili L; Ribeiro RRE; Dias AR; Zilberstein B; Ribeiro U; Cecconello I; Alves VAF; Mello ES
J Surg Res; 2021 May; 261():130-138. PubMed ID: 33429221
[TBL] [Abstract] [Full Text] [Related]
11. gastric adenocarcinoma of the fundic gland type: clinicopathological features of eight patients treated with endoscopic submucosal dissection.
Li C; Wu X; Yang S; Yang X; Yao J; Zheng H
Diagn Pathol; 2020 Oct; 15(1):131. PubMed ID: 33097069
[TBL] [Abstract] [Full Text] [Related]
12. Clinicopathological heterogeneity between primary and metastatic sites of gastroenteropancreatic neuroendocrine neoplasm.
Shi H; Jiang C; Zhang Q; Qi C; Yao H; Lin R
Diagn Pathol; 2020 Sep; 15(1):108. PubMed ID: 32917216
[TBL] [Abstract] [Full Text] [Related]
13. Pediatric gastroenteropancreatic neuroendocrine tumor: A case report and review of the literature.
Gaiani F; de'Angelis N; Minelli R; Kayali S; Carra MC; de'Angelis GL
Medicine (Baltimore); 2019 Sep; 98(37):e17154. PubMed ID: 31517859
[TBL] [Abstract] [Full Text] [Related]
14. Risk factors predisposing to cardia gastric adenocarcinoma: Insights and new perspectives.
Abdi E; Latifi-Navid S; Zahri S; Yazdanbod A; Pourfarzi F
Cancer Med; 2019 Oct; 8(13):6114-6126. PubMed ID: 31448582
[TBL] [Abstract] [Full Text] [Related]
15. Α-fetoprotein producing hepatoid gastric adenocarcinoma with neuroendocrine differentiation: A case report.
Li T; Liu T; Wang M; Zhang M
Medicine (Baltimore); 2018 Sep; 97(37):e12359. PubMed ID: 30212993
[TBL] [Abstract] [Full Text] [Related]
16. Metastatic neuroendocrine pancreatic tumor - Case report.
Radu EC; Saizu AI; Grigorescu RR; Croitoru AE; Gheorghe C
J Med Life; 2018; 11(1):57-61. PubMed ID: 29696066
[No Abstract] [Full Text] [Related]
17. Characterization of tissue chromogranin A (cga) immunostaining and clinicohistopathological changes for the 125 Chinese patients with primary small cell carcinoma of the esophagus.
Ku JW; Zhang DY; Song X; Li XM; Zhao XK; Lv S; Hu SJ; Cheng R; Zhou FY; Wu HF; Wang LD
Dis Esophagus; 2017 Aug; 30(8):1-7. PubMed ID: 28575250
[TBL] [Abstract] [Full Text] [Related]
18. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.
Walter T; Tougeron D; Baudin E; Le Malicot K; Lecomte T; Malka D; Hentic O; Manfredi S; Bonnet I; Guimbaud R; Coriat R; Lepère C; Desauw C; Thirot-Bidault A; Dahan L; Roquin G; Aparicio T; Legoux JL; Lombard-Bohas C; Scoazec JY; Lepage C; Cadiot G;
Eur J Cancer; 2017 Jul; 79():158-165. PubMed ID: 28501762
[TBL] [Abstract] [Full Text] [Related]
19. Baseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors.
Rogowski W; Wachuła E; Lewczuk A; Kolasińska-Ćwikła A; Iżycka-Świeszewska E; Sulżyc-Bielicka V; Ćwikła JB
Future Oncol; 2017 May; 13(12):1069-1079. PubMed ID: 28095720
[TBL] [Abstract] [Full Text] [Related]
20. Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors.
Tian T; Gao J; Li N; Li Y; Lu M; Li Z; Lu Z; Li J; Shen L
PLoS One; 2016; 11(5):e0154679. PubMed ID: 27159453
[TBL] [Abstract] [Full Text] [Related]
[Next]
